This invention relates generally to novel EMI tank filter assemblies, particularly of the type used in active medical devices (AMDs) such as cardiac pacemakers, cardioverter defibrillators, neurostimulators, externally worn Holter monitors and the like, which decouple lead wires and/or electronic components of the medical device from undesirable electromagnetic interference (EMI) signals at a selected frequency or frequencies, such as the RF pulsed fields of Magnetic Resonance Imaging (MRI) equipment.
Compatibility of cardiac pacemakers, implantable defibrillators and other types of active implantable medical devices with magnetic resonance imaging (MRI) and other types of hospital diagnostic equipment has become a major issue. If one goes to the websites of the major cardiac pacemaker manufacturers in the United States, which include St. Jude Medical, Medtronic and Boston Scientific (formerly Guidant), one will see that the use of MRI is generally contra-indicated with pacemakers and implantable defibrillators. See also:
(1) “Safety Aspects of Cardiac Pacemakers in Magnetic Resonance Imaging”, a dissertation submitted to the Swiss Federal Institute of Technology Zurich presented by Roger Christoph Lüchinger, Zurich 2002;
(2) “I. Dielectric Properties of Biological Tissues: Literature Survey”, by C. Gabriel, S. Gabriel and E. Cortout;
(3) “II. Dielectric Properties of Biological Tissues: Measurements and the Frequency Range 0 Hz to 20 GHz”, by S. Gabriel, R. W. Lau and C. Gabriel;
(4) “III. Dielectric Properties of Biological Tissues: Parametric Models for the Dielectric Spectrum of Tissues”, by S. Gabriel, R. W. Lau and C. Gabriel; and
(5) “Advanced Engineering Electromagnetics, C. A. Balanis, Wiley, 1989;
(6) Systems and Methods for Magnetic-Resonance-Guided Interventional Procedures, Patent Application Publication US 2003/0050557, Susil and Halperin et. al, published Mar. 13, 2003;
(7) Multifunctional Interventional Devices for MRI: A Combined Electrophysiology/MRI Catheter, by, Robert C. Susil, Henry R. Halperin, Christopher J. Yeung, Albert C. Lardo and Ergin Atalar, MRI in Medicine, 2002; and
(8) Multifunctional Interventional Devices for Use in MRI, U.S. Patent Application Ser. No. 60/283,725, filed Apr. 13, 2001.
The contents of the foregoing are all incorporated herein by reference.
However, an extensive review of the literature indicates that MRI is indeed often used with pacemaker, neurostimulator and other active implantable medical device (AIMD) patients. The safety and feasibility of MRI in patients with cardiac pacemakers is an issue of gaining significance. The effects of MRI on patients' pacemaker systems have only been analyzed retrospectively in some case reports. There are a number of papers that indicate that MRI on new generation pacemakers can be conducted up to 0.5 Tesla (T). MRI is one of medicine's most valuable diagnostic tools. MRI is, of course, extensively used for imaging, but is also used for interventional medicine (surgery). In addition, MRI is used in real time to guide ablation catheters, neurostimulator tips, deep brain probes and the like. An absolute contra-indication for pacemaker patients means that pacemaker and ICD wearers are excluded from MRI. This is particularly true of scans of the thorax and abdominal areas. Because of MRI's incredible value as a diagnostic tool for imaging organs and other body tissues, many physicians simply take the risk and go ahead and perform MRI on a pacemaker patient. The literature indicates a number of precautions that physicians should take in this case, including limiting the power of the MRI RF Pulsed field (Specific Absorption Rate—SAR level), programming the pacemaker to fixed or asynchronous pacing mode, and then careful reprogramming and evaluation of the pacemaker and patient after the procedure is complete. There have been reports of latent problems with cardiac pacemakers or other AIMDs after an MRI procedure sometimes occurring many days later. Moreover, there are a number of recent papers that indicate that the SAR level is not entirely predictive of the heating that would be found in implanted lead wires or devices. For example, for magnetic resonance imaging devices operating at the same magnetic field strength and also at the same SAR level, considerable variations have been found relative to heating of implanted lead wires. It is speculated that SAR level alone is not a good predictor of whether or not an implanted device or its associated lead wire system will overheat.
There are three types of electromagnetic fields used in an MRI unit. The first type is the main static magnetic field designated B0 which is used to align protons in body tissue. The field strength varies from 0.5 to 3.0 Tesla in most of the currently available MRI units in clinical use. Some of the newer MRI system fields can go as high as 4 to 5 Tesla. At the recent International Society for Magnetic Resonance in Medicine (ISMRM), which was held on 5 and 6 Nov. 2005, it was reported that certain research systems are going up as high as 11.7 Tesla and will be ready sometime in 2006. This is over 100,000 times the magnetic field strength of the earth. A static magnetic field can induce powerful mechanical forces and torque on any magnetic materials implanted within the patient. This would include certain components within the cardiac pacemaker itself and or lead wire systems. It is not likely (other than sudden system shut down) that the static MRI magnetic field can induce currents into the pacemaker lead wire system and hence into the pacemaker itself. It is a basic principle of physics that a magnetic field must either be time-varying as it cuts across the conductor, or the conductor itself must move within the magnetic field for currents to be induced.
The second type of field produced by magnetic resonance imaging is the pulsed RF field which is generated by the body coil or head coil. This is used to change the energy state of the protons and illicit MRI signals from tissue. The RF field is homogeneous in the central region and has two main components: (1) the magnetic field is circularly polarized in the actual plane; and (2) the electric field is related to the magnetic field by Maxwell's equations. In general, the RF field is switched on and off during measurements and usually has a frequency of 21 MHz to 64 MHz to 128 MHz depending upon the static magnetic field strength. The frequency of the RF pulse varies with the field strength of the main static field where: RF PULSED FREQUENCY in MHz=(42.56) (STATIC FIELD STRENGTH IN TESLA).
The third type of electromagnetic field is the time-varying magnetic gradient fields designated B1 which are used for spatial localization. These change their strength along different orientations and operating frequencies on the order of 1 kHz. The vectors of the magnetic field gradients in the X, Y and Z directions are produced by three sets of orthogonally positioned coils and are switched on only during the measurements. In some cases, the gradient field has been shown to elevate natural heart rhythms (heart beat). This is not completely understood, but it is a repeatable phenomenon. The gradient field is not considered by many researchers to create any other adverse effects.
It is instructive to note how voltages and EMI are induced into an implanted lead wire system. At very low frequency (VLF), voltages are induced at the input to the cardiac pacemaker as currents circulate throughout the patient's body and create voltage drops. Because of the vector displacement between the pacemaker housing and, for example, the TIP electrode, voltage drop across the resistance of body tissues may be sensed due to Ohms Law and the circulating current of the RF signal. At higher frequencies, the implanted lead wire systems actually act as antennas where currents are induced along their length. These antennas are not very efficient due to the damping effects of body tissue; however, this can often be offset by extremely high power fields (such as MRI pulsed fields) and/or body resonances. At very high frequencies (such as cellular telephone frequencies), EMI signals are induced only into the first area of the lead wire system (for example, at the header block of a cardiac pacemaker). This has to do with the wavelength of the signals involved and where they couple efficiently into the system.
Magnetic field coupling into an implanted lead wire system is based on loop areas. For example, in a cardiac pacemaker, there is a loop formed by the lead wire as it comes from the cardiac pacemaker housing to its distal TIP, for example, located in the right ventricle. The return path is through body fluid and tissue generally straight from the TIP electrode in the right ventricle back up to the pacemaker case or housing. This forms an enclosed area which can be measured from patient X-rays in square centimeters. The average loop area is 200 to 225 square centimeters. This is an average and is subject to great statistical variation. For example, in a large adult patient with an abdominal implant, the implanted loop area is much larger (greater than 450 square centimeters).
Relating now to the specific case of MRI, the magnetic gradient fields would be induced through enclosed loop areas. However, the pulsed RF fields, which are generated by the body coil, would be primarily induced into the lead wire system by antenna action.
There are a number of potential problems with MRI, including:
There are additional problems possible with implantable cardioverter defibrillators (ICDs). ICDs use different and larger batteries which could cause higher magnetic forces. The programmable sensitivity in ICDs is normally much higher (more sensitive) than it is for pacemakers, therefore, ICDs may falsely detect a ventricular tacchyarrhythmia and inappropriately deliver therapy. In this case, therapy might include anti-tacchycardia pacing, cardio version or defibrillation (high voltage shock) therapies. MRI magnetic fields may prevent detection of a dangerous ventricular arrhythmia or fibrillation. There can also be heating problems of ICD leads which are expected to be comparable to those of pacemaker leads. Ablation of vascular walls is another concern. Fortunately, ICDs have a sort of built-in fail-safe mechanism. That is, during an MRI procedure, if they inadvertently sense the MRI fields as a dangerous ventricular arrhythmia, the ICD will attempt to charge up and deliver a high voltage shock. However, there is a transformer contained within the ICD that is necessary to function in order to charge up the high-energy storage capacitor contained within the ICD. In the presence of the main static field of the MRI the core of this transformer tends to saturate thereby preventing the high voltage capacitor from charging up. This makes it highly unlikely that an ICD patient undergoing an MRI would receive an inappropriate high voltage shock therapy. While ICDs cannot charge during MRI due to the saturation of their ferro-magnetic transformers, the battery will be effectively shorted and lose life. This is a highly undesirable condition.
In summary, there are a number of studies that have shown that MRI patients with active implantable medical devices, such as cardiac pacemakers, can be at risk for potential hazardous effects. However, there are a number of reports in the literature that MRI can be safe for imaging of pacemaker patients when a number of precautions are taken (only when an MRI is thought to be an absolute diagnostic necessity). These anecdotal reports are of interest, however, they are certainly not scientifically convincing that all MRI can be safe. As previously mentioned, just variations in the pacemaker lead wire length can significantly effect how much heat is generated. From the layman's point of view, this can be easily explained by observing the typical length of the antenna on a cellular telephone compared to the vertical rod antenna more common on older automobiles. The relatively short antenna on the cell phone is designed to efficiently couple with the very high frequency wavelengths (approximately 950 MHz) of cellular telephone signals. In a typical AM and FM radio in an automobile, these wavelength signals would not efficiently couple to the relatively short antenna of a cell phone. This is why the antenna on the automobile is relatively longer. An analogous situation exists with an AIMD patient in an MRI system. If one assumes, for example, a 3.0 Tesla MRI system, which would have an RF pulsed frequency of 128 MHz, there are certain implanted lead lengths that would couple efficiently as fractions of the 128 MHz wavelength. It is typical that a hospital will maintain an inventory of various leads and that the implanting physician will make a selection depending on the size of the patient, implant location and other factors. Accordingly, the implanted or effective lead wire length can vary considerably. There are certain implanted lead wire lengths that just do not couple efficiently with the MRI frequency and there are others that would couple very efficiently and thereby produce the worst case for heating.
The effect of an MRI system on the function of pacemakers, ICDs and neurostimulators depends on various factors, including the strength of the static magnetic field, the pulse sequence (gradient and RF field used), the anatomic region being imaged, and many other factors. Further complicating this is the fact that each patient's condition and physiology is different and each manufacturer's pacemaker and ICD designs also are designed and behave differently. Most experts still conclude that MRI for the pacemaker patient should not be considered safe. Paradoxically, this also does not mean that the patient should not receive MRI. The physician must make an evaluation given the pacemaker patient's condition and weigh the potential risks of MRI against the benefits of this powerful diagnostic tool. As MRI technology progresses, including higher field gradient changes over time applied to thinner tissue slices at more rapid imagery, the situation will continue to evolve and become more complex. An example of this paradox is a pacemaker patient who is suspected to have a cancer of the lung. RF ablation treatment of such a tumor may require stereotactic imaging only made possible through real time fine focus MRI. With the patient's life literally at risk, the physician with patient informed consent may make the decision to perform MRI in spite of all of the previously described attendant risks to the pacemaker system.
Insulin drug pump systems do not seem to be of a major current concern due to the fact that they have no significant antenna components (such as implanted lead wires). However, some implantable pumps work on magneto-peristaltic systems, and must be deactivated prior to MRI. There are newer (unreleased) systems that would be based on solenoid systems which will have similar problems.
It is clear that MRI will continue to be used in patients with both external and active implantable medical devices. There are a number of other hospital procedures, including electrocautery surgery, lithotripsy, etc., to which a pacemaker patient may also be exposed. Accordingly, there is a need for AIMD system and/or circuit protection devices which will improve the immunity of active implantable medical device systems to diagnostic procedures such as MRI.
As one can see, many of the undesirable effects in an implanted lead wire system from MRI and other medical diagnostic procedures are related to undesirable induced currents in the lead wire system and/or its distal TIP (or RING). This can lead to overheating either in the lead wire or at the body tissue at the distal TIP. For a pacemaker application, these currents can also directly stimulate the heart into sometimes dangerous arrhythmias.
Accordingly, there is a need for a novel resonant tank band stop filter assembly which can be placed at various locations along the active implantable medical device lead wire system, which also prevents current from circulating at selected frequencies of the medical therapeutic device. Preferably, such novel tank filters would be designed to resonate at 64 MHz for use in an MRI system operating at 1.5 Tesla (or 128 MHz for a 3 Tesla system). The present invention fulfills these needs and provides other related advantages.
The present invention comprises resonant tank circuits/band stop filters to be placed at one or more locations along the active medical device (AMD) lead wire system, including its distal Tip. These band stop filters prevent current from circulating at selected frequencies of the medical therapeutic device. For example, for an MRI system operating at 1.5 Tesla, the pulse RF frequency is 64 MHz. The novel band stop filters of the present invention can be designed to resonate at 64 MHz and thus create an open circuit in the lead wire system at that selected frequency. For example, the band stop filter of the present invention, when placed at the distal TIP, will prevent currents from flowing through the distal TIP, prevent currents from flowing in the lead wires and also prevent currents from flowing into body tissue. It will be obvious to those skilled in the art that all of the embodiments described herein are equally applicable to a wide range of other active implantable or external medical devices, including deep brain stimulators, spinal cord stimulators, cochlear implants, ventricular assist devices, artificial hearts, drug pumps, Holter monitors and the like. The present invention fulfills all of the needs regarding reduction or elimination of undesirable currents and associated heating in implanted lead wire systems. The band stop filter structures as described herein also have a broad application to other fields, including telecommunications, military, space and the like.
Electrically engineering a capacitor in parallel with an inductor is known as a tank filter. It is also well known that when the tank filter is at its resonant frequency, it will present a very high impedance. This is a basic principle of all radio receivers. In fact, multiple tank filters are often used to improve the selectivity of a radio receiver. One can adjust the resonant frequency of the tank circuit by either adjusting the capacitor value or the inductor value or both. Since medical diagnostic equipment which is capable of producing very large fields operates at discrete frequencies, this is an ideal situation for a specific tank or band stop filter. Band stop filters are more efficient for eliminating one single frequency than broadband filters. Because the band stop filter is targeted at this one frequency or range of frequencies, it can be much smaller and volumetrically efficient. In addition, the way MRI RF pulse fields couple with lead wire systems, various loops and associated loop currents result along various sections of the lead wire. For example, at the distal TIP of a cardiac pacemaker, direct electromagnetic forces (EMF) can be produced which result in current loops through the distal TIP and into the associated myocardial tissue. This current system is largely decoupled from the currents that are induced near the active implantable medical device, for example, near the cardiac pacemaker. There the MRI may set up a separate loop with its associated currents. Accordingly, one or more band stop filters may be required to completely control all of the various induced EMI and associated currents in a lead wire system.
The present invention which resides in band stop filters is also designed to work in concert with the EMI filter which is typically used at the point of lead wire ingress and egress of the active implantable medical device. For example, see U.S. Pat. Nos. 5,333,095, entitled FEEDTHROUGH FILTER CAPACITOR ASSEMBLY FOR HUMAN IMPLANT; 6,999,818, entitled INDUCTOR CAPACITOR EMI FILTER FOR HUMAN IMPLANT APPLICATIONS; U.S. patent application Ser. No. 11/097,999 filed Mar. 31, 2005, entitled APPARATUS AND PROCESS FOR REDUCING THE SUSCEPTIBILITY OF ACTIVE IMPLANTABLE MEDICAL DEVICES TO MEDICAL PROCEDURES SUCH AS MAGNETIC RESONANCE IMAGING; and U.S. patent application Ser. No. 11/163,915 filed Nov. 3, 2005, entitled PROCESS FOR TUNING AN EMI FILTER TO REDUCE THE AMOUNT OF HEAT GENERATED IN IMPLANTED LEAD WIRES DURING MEDICAL PROCEDURES SUCH AS MAGNETIC RESONANCE IMAGING; the contents of all being incorporated herein by reference. All of these patent documents describe novel inductor capacitor combinations for low pass EMI filter circuits. It is of particular interest that by increasing the number of circuit elements, one can reduce the overall capacitance value which is at the input to the implantable medical device. It is important to reduce the capacitance value to raise the input impedance of the active implantable medical device such that this also reduces the amount of current that would flow in lead wire systems associated with medical procedures such as MRI. Accordingly, it is a feature of the present invention that the novel band stop filters are designed to be used in concert with the structures described in the above mentioned three patent applications.
As described in U.S. Patent Publication No. 2003/0050557 and U.S. Patent Application Ser. No. 60/283,725, the present invention is also applicable to probes and catheters. For example, ablation probes are used to selectively cauterize or ablate tissue on the inside or outside of the heart to control erratic electrical pulses. These procedures are best performed during real time fluoroscopy or MRI imaging. However, a major concern is the overheating of the distal TIP at inappropriate times because of the induced currents from the MRI system. It will be obvious to one skilled in the art that the novel band stop filters of the present invention can be adapted to any probe, TIP or catheter that is used in the human body.
Moreover, the present invention is also applicable to a number of external leads that might be placed on a patient during MRI. For example, patients frequently wear Holter monitors to monitor their cardiac activity over a period of days. It is an aggravation to physicians to have a patient sent up to the MRI Department and have all these carefully placed electrodes removed from the patient's body. Typically the MRI technicians are concerned about leaving these leads on during an MRI because they don't want them to overheat and cause surface burns on the patient's skin. The problem is that after the MRI procedure, the MRI technicians often replace these electrodes or skin patches in different or even in the wrong locations. This greatly confounds the cardiac physician because now the Holter monitor results are no longer consistent. It is a feature of the present invention that the tank filters could be placed in any externally worn lead wires by the patient during an MRI procedure such that they do not need to be removed.
In one embodiment, the invention provides a medical therapeutic device comprising an active medical device (AMD), a lead wire extending from the AMD to a distal TIP thereof, and a band stop filter associated with the lead wire for attenuating current flow through the lead wire at a selected frequency.
The AMD may comprise cochlear implants, piezoelectric sound bridge transducers, neurostimulators, brain stimulators, cardiac pacemakers, ventricular assist devices, artificial hearts, drug pumps, bone growth stimulators, bone fusion stimulators, urinary incontinence devices, pain relief spinal cord stimulators, anti-tremor stimulators, gastric stimulators, implantable cardioverter defibrillators, pH probes, congestive heart failure devices, pill cameras, neuromodulators, cardiovascular stents, orthopedic implants, external insulin pumps, external drug pumps, external neurostimulators, and external probes or catheters.
The band stop filter itself comprises a capacitor (and its resistance or an added resistance) in parallel with an inductor (and its parasitic resistance), said parallel capacitor and inductor combination being placed in series with the medical device lead wire(s) wherein the values of capacitance and inductance have been selected such that the band stop filter is resonant at a selected frequency (such as the MRI pulsed frequency).
In the preferred embodiment, the Q of the inductor is relatively maximized and the Q of the capacitor is relatively minimized to reduce the overall Q of the band stop filter. The Q of the inductor is relatively maximized by minimizing the parasitic resistive loss in the inductor, and the Q of the capacitor is relatively minimized by raising its equivalent series resistance (ESR) of the capacitor (or by adding resistance or a resistive element in series with the capacitor element of the band stop tank filter). This reduces the overall Q of the band stop filter in order to broaden its 3 dB points and thereby attenuate current flow through the lead wire along a range of selected frequencies. In AIMD or external medical device applications, the range of selected frequencies includes a plurality of MRI pulsed frequencies.
The equivalent series resistance of the capacitor is raised by any of the following: reducing thickness of electrode plates in the capacitor; using higher resistivity capacitor electrode materials, providing apertures, gaps, slits or spokes in the electrode plates of the capacitor; providing separate discrete resistors in series with the capacitor; utilizing resistive electrical attachment materials to the capacitor; or utilizing capacitor dielectric materials that have high dielectric loss tangents at the selected frequency. Methods of using higher resistivity capacitor electrode materials include, for example, using platinum instead of silver electrodes. Platinum has a higher volume resistivity as compared to pure silver. Another way of reducing capacitor electrode plate resistivity is to add ceramic powders to the electrode ink before it is silk screened down and fired. After firing, this has the effect of separating the conductive electrode portions by insulative dielectric areas which increases the overall resistivity of the electrode plate.
As defined herein, raising the capacitor ESR includes any or all of the above described methods of adding resistance in series with the capacitive element of the band stop filter. It should be noted that deliberately raising the capacitor ESR runs counter to conventional/prior art capacitor technologies. In fact, capacitor manufacturers generally strive to build capacitors with as low an ESR as possible. This is to minimize energy loss, etc. It is a feature of the present invention that capacitor Q is raised in a controlled manner in the tank filter circuit in order to adjust its Q and adjust the band stop frequency width in the range of MRI pulsed frequencies.
Preferably, the band stop filter is disposed adjacent to the distal tip of the lead wire and is integrated into a TIP electrode. It may also be integrated into one or more RING electrodes. The lead wire may also comprise an externally worn lead wire, or it may come from an externally worn electronics module wherein said lead penetrates through the skin surface to an implanted distal electrode.
The present invention also provides a novel process for attenuating current flow through a lead wire for an active medical device at a selected frequency, comprising the steps of: selecting a capacitor which is resonant at the selected frequency; selecting an inductor which is resonant at the selected frequency; using the capacitor and the inductor to form a tank filter circuit; and placing the tank filter circuit in series with the lead wire.
The overall Q of the tank filter circuit may be reduced by increasing the Q of the inductor and reducing the Q of the capacitor. In this regard, minimizing resistive loss in the inductor maximizes the Q of the inductor, and raising the equivalent series resistance of the capacitor minimizes the Q of the capacitor.
The net effect is to reduce the overall Q of the tank filter circuit which widens the band stop width to attenuate current flow through the lead wire along a range of selected frequencies. As discussed herein, the range of selected frequencies may include a plurality of MRI pulse frequencies.
Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, the principles of the invention.
The accompanying drawings illustrate the invention. In such drawings:
Referring now to
The IS1 connectors 110 that are designed to plug into the header block 112 are low voltage (pacemaker) connectors covered by an ANSI/AAMI standard IS-1. Higher voltage devices, such as implantable cardioverter defibrillators, are covered by a standard known as the ANSI/AAMI DF-1. There is a new standard under development which will integrate both high voltage and low voltage connectors into a new miniature connector series known as the IS-4 series. These connectors are typically routed in a pacemaker application down into the right ventricle and right atrium of the heart 114. There are also new generation devices that have been introduced to the market that couple lead wires to the outside of the left ventricle. These are known as biventricular devices and are very effective in cardiac resynchronization therapy (CRT) and treating congestive heart failure (CHF).
Referring once again to
It should also be obvious to those skilled in the art that all of the descriptions herein are equally applicable to other types of AIMDs. These include implantable cardioverter defibrillators (ICDs), neurostimulators, including deep brain stimulators, spinal cord stimulators, cochlear implants, incontinence stimulators and the like, and drug pumps. The present invention is also applicable to a wide variety of minimally invasive AIMDs. For example, in certain hospital cath lab procedures, one can insert an AIMD for temporary use such as an ICD. Ventricular assist devices also can fall into this type of category. This list is not meant to be limiting, but is only example of the applications of the novel technology currently described herein.
Referring back to
It is also essential that the lead wires 104 and insulator 136 be hermetically sealed, such as by the gold brazes or glass seals 132 and 134. The gold braze 132 wets from the titanium ferrule 108 to the alumina ceramic insulator 136. In turn, the ceramic alumina insulator 136 is also gold brazed at 134 to each of the lead wires 104. The RF telemetry pin 116 is also gold brazed at 138 to the alumina ceramic insulator 136. It will be obvious to those skilled in the art that there are a variety of other ways of making such a hermetic terminal. This would include glass sealing the leads into the ferrule directly without the need for the gold brazes.
As shown in
In the following description, functionally equivalent elements shown in various embodiments will often be referred to utilizing the same reference number.
The distal TIP 142 is designed to be implanted into or affixed to the actual myocardial tissue of the heart. The RING 144 is designed to float in the blood pool. Because the blood is flowing and is thermally conductive, the RING 144 structure is substantially cooled. In theory, however, if the lead curves, the RING 144 could also touch and become encapsulated by body tissue. The distal TIP 142, on the other hand, is always thermally insulated by surrounding body tissue and can readily heat up due to the RF pulse currents of an MRI field.
Referring once again to
The relationship between the parallel inductor L and capacitor C is also very important. One could use, for example, a very large value of inductance which would result in a very small value of capacitance to be resonant, for example, at the MRI frequency of 64 MHz. However, using a very high value of inductor results in a high number of turns of very small wire. Using a high number of turns of very small diameter wire is contraindicated for two reasons. The first reason is that the long length of relatively small diameter wire results in a very high DC resistance for the inductor. This resistance is very undesirable because low frequency pacing or neurostimulator pulses would lose energy passing through the relatively high series resistance. This is also undesirable where the AIMD is sensing biologic signals. For example, in the case of a pacemaker or deep brain stimulator, continuous sensing of low frequency biological signals is required. Too much series resistance in a lead wire system will attenuate such signals thereby making the AIMD less efficient. Accordingly, it is a preferred feature of the present invention that a relatively large value of capacitance will be used in parallel with a relatively small value of inductance, for example, employing highly volumetrically efficient ceramic dielectric capacitors that can create a great deal of capacitance in a very small space.
It should be also noted that below resonance, particularly at very low frequencies, the current in the parallel L-C band width stop filter passes through the inductor element. Accordingly, it is important that the parasitic resistance of the inductor element be quite low. Conversely, at very low frequencies, no current passes through the capacitor element. At high frequencies, the reactance of the capacitor element drops to a very low value. However, as there is no case where it is actually desirable to have high frequencies pass through the tank filter, the parasitic resistive loss of the capacitor is not particularly important. This is also known as the capacitor's equivalent series resistance (ESR). A component of capacitor ESR is the dissipation factor of the capacitor (a low frequency phenomena). Off of resonance, it is not particularly important how high the capacitor's dissipation factor or overall ESR is when used as a component of a parallel tank circuit 146 as described herein. Accordingly, an air wound inductor is the ideal choice because it is not affected by MRI signals or fields. Because of the space limitations, however, the inductor will not be very volumetrically efficient. For this reason, it is preferable to keep the inductance value relatively low (in the order of 1 to 100 nanohenries).
Referring once again to
This is best understood by looking at the
In the case where one has gone through the left hand decision tree consisting of blocks 150, 152 and 154 a number of times and keeps coming up with a “no,” then one has to assume a realizable value of inductance and go to the right hand decision tree starting at block 156. One then assumes a realizable value of inductance (L) with a low enough series resistance for the inductor RL such that it will work and fit into the design space and guidelines. After one assumes that value of inductance, one then goes to decision block 158 and solves the equation C in
For purposes of the present invention, it is possible to use series discrete inductors or parallel discrete capacitors to achieve the same overall result. For example, in the case of the inductor element L, it would be possible to use two, three or even more (n) individual inductor elements in series. The same is true for the capacitor element that appears in the parallel tank filter 146. By adding or subtracting capacitors in parallel, we are also able to adjust the total capacitance that ends up resonating in parallel with the inductance.
It is also possible to use a single inductive component that has significant parasitic capacitance between its adjacent turns. A careful designer using multiple turns could create enough parasitic capacitance such that the coil becomes self-resonant at a predetermined frequency. In this case, the predetermined frequency would be the MRI pulsed frequency.
Efficiency of the overall tank circuit 146 is also measured in terms of a quality factor, Q, although this factor is defined differently than the one previously mentioned for discrete capacitors and inductors. The circuit Q is typically expressed using the following equation:
Where fr is the resonance frequency, and Δf3dB shown as points a and b in
Material and application parameters must be taken into consideration when designing tank filters. Most capacitor dielectric materials age 1%-5% in capacitance values per decade of time elapsed, which can result in a shift of the resonance frequency of upwards of 2.5%. In a high-Q filter, this could result in a significant and detrimental drop in the band stop filter performance. A lower-Q filter would minimize the effects of resonance shift and would allow a wider frequency band through the filter. However, very low Q filters display lower than desirable attenuation behavior at the desired band stop frequency (see
Accordingly, the “Q” or quality factor of the tank circuit is very important. As mentioned, it is desirable to have a very low loss circuit at low frequencies such that the biological signals not be undesirably attenuated. The quality factor not only determines the loss of the filter, but also affects its 3 dB bandwidth. If one does a plot of the filter response curve (Bode plot), the 3 dB bandwidth determines how sharply the filter will rise and fall. With reference to curve 166 of
The performance of the circuit is directly related to the efficiency of both the inductor and the capacitor; the less efficient each component is, the more heat loss that results, and this can be expressed by the addition of resistor elements to the ideal circuit diagram. The effect of lower Q in the tank circuit is to broaden the resonance peak about the resonance frequency. By deliberately using a low Q capacitor, one can broaden the resonance such that a high impedance (high attenuation) is presented at multiple MRI RF frequencies, for example 64 MHz and 128 MHz.
Referring again to
Referring once again to
Referring again to
Although several embodiments of the invention have been described in detail, for purposes of illustration, various modifications of each may be made without departing from the spirit and scope of the invention. Accordingly, the invention is not to be limited, except as by the appended claims.
This application is a division of U.S. Ser. No. 11/423,073, filed on Jun. 8, 2006, now U.S. Pat. No. 8,244,370.
Number | Name | Date | Kind |
---|---|---|---|
3871382 | Mann | Mar 1975 | A |
3968802 | Ballis | Jul 1976 | A |
3980975 | Maxon, Jr. et al. | Sep 1976 | A |
4236127 | Scherba | Nov 1980 | A |
4437474 | Peers-Trevarton | Mar 1984 | A |
4633181 | Murphy-Boesch et al. | Dec 1986 | A |
4654880 | Sontag | Mar 1987 | A |
4689621 | Kleinberg | Aug 1987 | A |
4712555 | Thornander et al. | Dec 1987 | A |
4746864 | Satoh | May 1988 | A |
4788980 | Mann et al. | Dec 1988 | A |
4799499 | Bisping | Jan 1989 | A |
4858623 | Bradshaw et al. | Aug 1989 | A |
4940052 | Mann et al. | Jul 1990 | A |
4944298 | Sholder | Jul 1990 | A |
4991580 | Moore | Feb 1991 | A |
5044375 | Bach, Jr. et al. | Sep 1991 | A |
5052404 | Hodgson | Oct 1991 | A |
5063348 | Kuhara et al. | Nov 1991 | A |
5209233 | Holland et al. | May 1993 | A |
5217010 | Tsitlik et al. | Jun 1993 | A |
5222506 | Patrick et al. | Jun 1993 | A |
5246438 | Langberg | Sep 1993 | A |
5300108 | Rebell et al. | Apr 1994 | A |
5306291 | Kroll et al. | Apr 1994 | A |
5333095 | Stevenson et al. | Jul 1994 | A |
5363845 | Chowdhury et al. | Nov 1994 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5404880 | Throne | Apr 1995 | A |
5428337 | Vinclarelli et al. | Jun 1995 | A |
5466254 | Helland | Nov 1995 | A |
5476483 | Bornzin et al. | Dec 1995 | A |
5514173 | Rebell et al. | May 1996 | A |
5545201 | Helland et al. | Aug 1996 | A |
5620476 | Truex et al. | Apr 1997 | A |
5629622 | Scampini | May 1997 | A |
5697958 | Paul et al. | Dec 1997 | A |
5716390 | Li | Feb 1998 | A |
5722998 | Prutchi et al. | Mar 1998 | A |
5741321 | Brennen | Apr 1998 | A |
5751539 | Stevenson et al. | May 1998 | A |
5759202 | Schroeppel | Jun 1998 | A |
5782891 | Hassler et al. | Jul 1998 | A |
5800467 | Park et al. | Sep 1998 | A |
5824026 | Diaz | Oct 1998 | A |
5836992 | Thompson et al. | Nov 1998 | A |
5851226 | Skubitz et al. | Dec 1998 | A |
5905627 | Brendel et al. | May 1999 | A |
5959829 | Stevenson et al. | Sep 1999 | A |
5964705 | Truwit et al. | Oct 1999 | A |
5973906 | Stevenson et al. | Oct 1999 | A |
5978204 | Stevenson | Nov 1999 | A |
6008980 | Stevenson et al. | Dec 1999 | A |
6052614 | Morris, Sr. et al. | Apr 2000 | A |
6055457 | Bonner | Apr 2000 | A |
6101417 | Vogel et al. | Aug 2000 | A |
6141594 | Flynn et al. | Oct 2000 | A |
6159560 | Stevenson et al. | Dec 2000 | A |
6198972 | Hartlaub et al. | Mar 2001 | B1 |
6209764 | Hartlaub et al. | Apr 2001 | B1 |
6236205 | Luedeke et al. | May 2001 | B1 |
6275369 | Stevenson et al. | Aug 2001 | B1 |
6280385 | Melzer et al. | Aug 2001 | B1 |
6395637 | Park et al. | May 2002 | B1 |
6414835 | Wolf et al. | Jul 2002 | B1 |
6424234 | Stevenson | Jul 2002 | B1 |
6433653 | Matsumura et al. | Aug 2002 | B1 |
6456481 | Stevenson | Sep 2002 | B1 |
6459935 | Piersma | Oct 2002 | B1 |
6473291 | Stevenson | Oct 2002 | B1 |
6486529 | Chi et al. | Nov 2002 | B2 |
6493591 | Stokes | Dec 2002 | B1 |
6529103 | Brendel et al. | Mar 2003 | B1 |
6535766 | Thompson et al. | Mar 2003 | B1 |
6539253 | Thompson et al. | Mar 2003 | B2 |
6566978 | Stevenson et al. | May 2003 | B2 |
6567259 | Stevenson et al. | May 2003 | B2 |
6567703 | Thompson et al. | May 2003 | B1 |
6606513 | Lardo et al. | Aug 2003 | B2 |
6615483 | Lindegren | Sep 2003 | B2 |
6643903 | Stevenson et al. | Nov 2003 | B2 |
6675033 | Lardo et al. | Jan 2004 | B1 |
6675036 | Kreger et al. | Jan 2004 | B2 |
6675779 | King et al. | Jan 2004 | B2 |
6675780 | Wendels et al. | Jan 2004 | B1 |
6687550 | Doan | Feb 2004 | B1 |
6697675 | Safarevich et al. | Feb 2004 | B1 |
6701176 | Halperin et al. | Mar 2004 | B1 |
6728575 | Hedberg | Apr 2004 | B2 |
6728579 | Lindgren et al. | Apr 2004 | B1 |
6765780 | Brendel et al. | Jul 2004 | B2 |
6795730 | Connelly et al. | Sep 2004 | B2 |
6823215 | Obel et al. | Nov 2004 | B2 |
6847837 | Melzer et al. | Jan 2005 | B1 |
6868288 | Thompson | Mar 2005 | B2 |
6876885 | Swoyer et al. | Apr 2005 | B2 |
6882248 | Stevenson et al. | Apr 2005 | B2 |
6898454 | Atalar et al. | May 2005 | B2 |
6925328 | Foster et al. | Aug 2005 | B2 |
6930242 | Helfer et al. | Aug 2005 | B1 |
6931283 | Magnusson | Aug 2005 | B1 |
6931286 | Sigg et al. | Aug 2005 | B2 |
6934588 | Brand et al. | Aug 2005 | B1 |
6944507 | Froberg et al. | Sep 2005 | B2 |
6949929 | Gray et al. | Sep 2005 | B2 |
6950696 | Bjoring et al. | Sep 2005 | B2 |
6952613 | Swoyer et al. | Oct 2005 | B2 |
6971391 | Wang et al. | Dec 2005 | B1 |
6985347 | Stevenson et al. | Jan 2006 | B2 |
6999818 | Stevenson et al. | Feb 2006 | B2 |
7012192 | Stevenson et al. | Mar 2006 | B2 |
7013180 | Villaseca et al. | Mar 2006 | B2 |
7015393 | Weiner et al. | Mar 2006 | B2 |
7039455 | Brosovich et al. | May 2006 | B1 |
7047073 | Hoijer et al. | May 2006 | B2 |
7050855 | Zeijlemaker et al. | May 2006 | B2 |
7091412 | Wang et al. | Aug 2006 | B2 |
7092766 | Salys et al. | Aug 2006 | B1 |
7113387 | Stevenson et al. | Sep 2006 | B2 |
7123013 | Gray | Oct 2006 | B2 |
7127294 | Wang et al. | Oct 2006 | B1 |
7148783 | Parsche et al. | Dec 2006 | B2 |
7149578 | Edvardsson | Dec 2006 | B2 |
7155271 | Halperin et al. | Dec 2006 | B2 |
7162302 | Wang et al. | Jan 2007 | B2 |
7164950 | Kroll et al. | Jan 2007 | B2 |
7310216 | Stevenson et al. | Dec 2007 | B2 |
7369898 | Kroll et al. | May 2008 | B1 |
7388378 | Gray et al. | Jun 2008 | B2 |
7529590 | MacDonald | May 2009 | B2 |
7561906 | Atalar et al. | Jul 2009 | B2 |
7702387 | Stevenson et al. | Apr 2010 | B2 |
7729770 | Cabelka et al. | Jun 2010 | B2 |
7839146 | Gray | Nov 2010 | B2 |
7844343 | Wahlstrand et al. | Nov 2010 | B2 |
8301249 | Min et al. | Oct 2012 | B2 |
20030013948 | Russell | Jan 2003 | A1 |
20030028094 | Kumar et al. | Feb 2003 | A1 |
20030050557 | Susil et al. | Mar 2003 | A1 |
20030083570 | Cho et al. | May 2003 | A1 |
20030083723 | Wilkinson et al. | May 2003 | A1 |
20030140931 | Zeijlemaker et al. | Jul 2003 | A1 |
20030144704 | Terry et al. | Jul 2003 | A1 |
20030144705 | Funke | Jul 2003 | A1 |
20030144706 | Funke | Jul 2003 | A1 |
20030144716 | Reinke et al. | Jul 2003 | A1 |
20030144718 | Zeijlemaker et al. | Jul 2003 | A1 |
20030144719 | Zeijlemaker | Jul 2003 | A1 |
20030144720 | Villaseca et al. | Jul 2003 | A1 |
20030144721 | Villaseca et al. | Jul 2003 | A1 |
20030204217 | Greatbatch | Oct 2003 | A1 |
20040088012 | Kroll et al. | May 2004 | A1 |
20040167392 | Halperin et al. | Aug 2004 | A1 |
20040210289 | Wang et al. | Oct 2004 | A1 |
20040230271 | Wang et al. | Nov 2004 | A1 |
20040249428 | Wang et al. | Dec 2004 | A1 |
20040263173 | Gray | Dec 2004 | A1 |
20040263174 | Gray et al. | Dec 2004 | A1 |
20050113669 | Helfer et al. | May 2005 | A1 |
20050113676 | Weiner et al. | May 2005 | A1 |
20050113873 | Weiner et al. | May 2005 | A1 |
20050113874 | Connelly et al. | May 2005 | A1 |
20050113876 | Weiner et al. | May 2005 | A1 |
20050197677 | Stevenson | Sep 2005 | A1 |
20050215914 | Bornzin et al. | Sep 2005 | A1 |
20050222642 | Przybyszewski et al. | Oct 2005 | A1 |
20050222647 | Wahlstrand et al. | Oct 2005 | A1 |
20050222656 | Wahlstrand et al. | Oct 2005 | A1 |
20050222657 | Wahlstrand et al. | Oct 2005 | A1 |
20050222659 | Olsen et al. | Oct 2005 | A1 |
20050247472 | Helfer et al. | Nov 2005 | A1 |
20050248340 | Berkcan et al. | Nov 2005 | A1 |
20060009819 | Przybyszewski | Jan 2006 | A1 |
20060025820 | Phillips et al. | Feb 2006 | A1 |
20060030774 | Gray et al. | Feb 2006 | A1 |
20060041294 | Gray | Feb 2006 | A1 |
20060085043 | Stevenson | Apr 2006 | A1 |
20060100506 | Halperin et al. | May 2006 | A1 |
20060119361 | Karmarkar et al. | Jun 2006 | A1 |
20060200218 | Wahlstrand et al. | Sep 2006 | A1 |
20060229693 | Bauer et al. | Oct 2006 | A1 |
20060247684 | Halperin et al. | Nov 2006 | A1 |
20060247747 | Olsen et al. | Nov 2006 | A1 |
20060247748 | Wahlstrand et al. | Nov 2006 | A1 |
20060252314 | Atalar et al. | Nov 2006 | A1 |
20060259093 | Stevenson et al. | Nov 2006 | A1 |
20060271138 | MacDonald | Nov 2006 | A1 |
20070035910 | Stevenson | Feb 2007 | A1 |
20070043399 | Stevenson et al. | Feb 2007 | A1 |
20070083244 | Stevenson et al. | Apr 2007 | A1 |
20070088416 | Atalar et al. | Apr 2007 | A1 |
20070093142 | MacDonald et al. | Apr 2007 | A1 |
20070106332 | Denker et al. | May 2007 | A1 |
20070112398 | Stevenson et al. | May 2007 | A1 |
20070123949 | Dabney et al. | May 2007 | A1 |
20070168006 | Gray | Jul 2007 | A1 |
20070179577 | Marshall et al. | Aug 2007 | A1 |
20070208383 | Williams | Sep 2007 | A1 |
20070255377 | Marshall et al. | Nov 2007 | A1 |
20070288058 | Halperin et al. | Dec 2007 | A1 |
20070299490 | Yang et al. | Dec 2007 | A1 |
20080004670 | McVenes et al. | Jan 2008 | A1 |
20080033497 | Bulkes et al. | Feb 2008 | A1 |
20080039709 | Karmarkar | Feb 2008 | A1 |
20080051854 | Bulkes et al. | Feb 2008 | A1 |
20080132986 | Gray et al. | Jun 2008 | A1 |
20080195186 | Li et al. | Aug 2008 | A1 |
20080195187 | Li et al. | Aug 2008 | A1 |
20080243218 | Bottomley et al. | Oct 2008 | A1 |
20080262584 | Bottomley et al. | Oct 2008 | A1 |
20080269591 | Halperin et al. | Oct 2008 | A1 |
20090099440 | Viohl | Apr 2009 | A1 |
20090099555 | Viohl et al. | Apr 2009 | A1 |
20090281592 | Vase | Nov 2009 | A1 |
20100010602 | Wedan et al. | Jan 2010 | A1 |
20100016936 | Stevenson et al. | Jan 2010 | A1 |
20100076538 | Desai et al. | Mar 2010 | A1 |
20100114276 | Min et al. | May 2010 | A1 |
20100114277 | Zhao et al. | May 2010 | A1 |
20100138192 | Min | Jun 2010 | A1 |
20100174348 | Bulkes et al. | Jul 2010 | A1 |
20100174349 | Stevenson et al. | Jul 2010 | A1 |
Number | Date | Country |
---|---|---|
0243573 | Nov 1987 | EP |
0145430 | May 1991 | EP |
0145430 | May 1991 | EP |
0 498 996 | Mar 1997 | EP |
0930509 | Dec 1998 | EP |
1021730 | Apr 1999 | EP |
1469910 | Dec 2006 | EP |
2025361 | Nov 2007 | EP |
1883449 | Jan 2009 | EP |
60141034 | Jul 1985 | JP |
61181925 | Aug 1986 | JP |
62233905 | Oct 1987 | JP |
4071536 | Mar 1992 | JP |
6054823 | Mar 1994 | JP |
11239572 | Sep 1999 | JP |
WO0919739 | Apr 1999 | WO |
WO 02083016 | Oct 2002 | WO |
WO03037424 | May 2003 | WO |
WO03063946 | Aug 2003 | WO |
WO03063952 | Aug 2003 | WO |
WO03063953 | Aug 2003 | WO |
WO03063955 | Aug 2003 | WO |
WO03063956 | Aug 2003 | WO |
WO03063957 | Aug 2003 | WO |
WO2005081784 | Sep 2005 | WO |
WO2005102445 | Nov 2005 | WO |
WO2005102446 | Nov 2005 | WO |
WO2005102447 | Nov 2005 | WO |
WO2005115531 | Dec 2005 | WO |
WO2006093685 | Sep 2006 | WO |
WO2007047966 | Apr 2007 | WO |
WO2007089988 | Aug 2007 | WO |
WO2007102893 | Sep 2007 | WO |
WO2007145671 | Dec 2007 | WO |
WO2008111986 | Sep 2008 | WO |
Entry |
---|
Ariel Roguin, et al., Modern Pacemaker and Implantable Cardioverter/Defibrillator Systems Can Be Magnetic Resonance Imaging Safe, Circulation—Journal of the American Heart Association, Aug. 4, 2004 (originally published online Jul. 26, 2004), pp. 475-482, American Heart Association, Dallas, Texas, USA. |
Roger Christoph Luchinger, Safety Aspects of Cardiac Pacemakers in Magnetic Resonance Imaging, a dissertation submitted to the Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, 2002. |
C. Gabriel, S. Gabriel and E. Cortout, I. Dielectric Properties of Biological Tissues: Literature Survey. |
S. Gabriel, R.W. Lau and C. Gabriel, II. Dielectric Properties of Biological Tissues: Measurements and the Frequency Range 0 Hz to 20 GHz. |
S. Gabriel, R.W. Lau and C. Gabriel, III. Dielectric Properties of Biological Tissues: Parametric Models for the Dielectric Spectrum of Tissues. |
Constantine A. Balanis, Advanced Engineering Electromagnetics, John Wiley & Sons, Inc. 1989. |
Robert C. Susil, Christopher J. Yeung, Henry R. Halperin, Albert C. Lardo, Ergin Atalar, Multifunctional Interventional Devices for MRI: A Combined Electrophysiology/MRI Catheter, Magnetic Resonance in Medicine, 2002, pp. 594-600, Wiley-Liss, Inc., Departments of Biomedical Engineering, Radiology & Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. |
Robert C. Susil, Ergin Atalar, Albert Lardo, Multifunctional Interventional Devices for Use in MRI, U.S. Appl. No. 60/283,725, filed Apr. 13, 2001. |
Massarini, Antonio, et al., Modelng The Parasitic Capacitance of Inductors—CARTS 96: 16th Capacitor and Resistor Technology Symposium, Mar. 11-15, 1996, pp. 78-84, New Orleans, Louisiana. |
Massarini, A, et al., Lumped Parameter Models for Single—and Multiple-Layer Inductors. Jun. 23-27, 1996, IEEE. |
Number | Date | Country | |
---|---|---|---|
20080269591 A1 | Oct 2008 | US |
Number | Date | Country | |
---|---|---|---|
60283725 | Apr 2001 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11423073 | Jun 2006 | US |
Child | 12170811 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10123534 | Apr 2002 | US |
Child | 11423073 | US |